Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Co.'s long-acting, local analgesic EXPAREL® (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, its extended release drug delivery technology, that delivers bupivacaine over time for extended analgesia. The PCRX stock yearly return is shown above.
The yearly return on the PCRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PCRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|